Generic, biosimilar and value-added medicines industry leadership reinforced as it prepares for the next framework agreement on pricing and supply of medicines and responds to
Patient access to medicines at risk due to the disproportionate impact of the UWWTD Extended Producer Responsibility (EPR) scheme on generic medicine suppliers Medicines for
Membership expansion bolsters expertise and voice of Ireland’s generic, biosimilar and value-added medicines industry ahead of pivotal negotiations with the State on pricing and supply
Suppliers of generic, biosimilar, and value-added medicines call on political parties to ensure fair competition through patent reform, which could potentially saving the State millions.
Medicines for Ireland, alongside our colleagues in Medicines for Europe, are seriously concerned about the impact of the Urban Wastewater Treatment Directive (UWWTD). The direct
With 1 in 5 individuals personally affected by medicines shortages in the last two years, Medicines for Ireland calls on the Department of Health and
Negotiation on the new Framework Agreement on Supply and Pricing of Medicines set to be a key priority for incoming Medicines for Ireland chair and
Medicines for Ireland (MFI) are highlighting the role of inflation, rising energy and transport costs, and persistent global supply chain disruptions which have combined to create a
Medicines for Ireland, the Irish pharmaceutical trade association and the supplier of the majority of medicines in Ireland, is proud to introduce Generic Medicines Day
We are committed to working with key stakeholders to affect real change and reforms that ensure Irish patients receive the best medical treatment in the most affordable way.
